Business Context and Reporting Period
Company: Capricor Therapeutics, Inc. (CAPR)
Filing Type: Form 8-K (Current Report)
Report Date: May 12, 2026
Reporting Period: First Quarter ended March 31, 2026
Business Context: The filing announces the release of financial results for the quarter ended March 31, 2026, and provides a corporate update via an attached press release (Exhibit 99.1).
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K. It references the existence of financial results but does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the attached press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms that a press release detailing these results was issued on May 12, 2026.
Guidance, Outlook, and Risks
Outlook and Commentary: The filing indicates that a "Corporate Update" was provided alongside the financial results in the attached press release. Specific guidance or management commentary is not present in the text provided.
Risks and Contingencies: No specific risks or contingencies are detailed in this excerpt. The filing includes a standard disclaimer that the information furnished under Item 2.02 is not deemed filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2026 revenue, net loss, and cash position figures.
- Verify the "Corporate Update" details regarding clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm the company's cash runway and any recent financing activities not detailed in this cover page.
- Check for any forward-looking statements or revised guidance provided in the full press release.